Back to search
FDAFDA · Food and drugs·Recall number D-0077-2021

Metformin HCl Extended Release Tablets USP 500 mg, Generic for : Glucophage XR, Pkg Size 100, Mfg: Time-Cap Labs, Inc.; Farmingdale, NY, NDC #: 68788-6932-1, Preferred Pharmaceuticals, Inc.

Published November 25, 2020 · Recall initiated: November 1, 2020

Summary

FDA records drug Class II recall D-0077-2021, published November 25, 2020 and initiated November 1, 2020. Recalling firm: Preferred Pharmaceuticals, Inc.; Status: Terminated; Reported quantity: 99 bottles (9990 Extended Release Tablets); Lot: E0620F, Exp.12/31/2021; G2020M Exp., 04/30/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Preferred Pharmaceuticals, Inc.
Distributor
Distributed to two physician's offices located in FL.
Lot
E0620F, Exp.12/31/2021; G2020M Exp., 04/30/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Metformin HCl Extended Release Tablets USP 500 mg, Generic for : Glucophage XR, Pkg Size 100, Mfg: Time-Cap Labs, Inc.; Farmingdale, NY, NDC #: 68788-6932-1, Preferred Pharmaceuticals, Inc. recalled?

Yes. FDA published recall D-0077-2021 on November 25, 2020. Reported hazard: CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.

What should I do if I have this product?

Voluntary: Firm initiated · Letter